Mito-lncRNAs have emerged as key regulators of cardiac

The gap

Evidence profile

Sourced from the future work of the source papers, classified as general, spanning 3 journals.

Supporting evidence — 3 representative gaps

• Mitochondrial translational control in cardiovascular diseases: from mechanisms to therapies (2026) · Redox Biology · doi

  Mitochondrial translation extends far beyond basic cellular house- keeping. In the highly oxidative myocardium, it operates as the ultimate checkpoint linking genomic output directly to metabolic demand. This precision relies entirely on the physical architecture of the IMM, where protein synthesis, complex assembly, and bioenergetics inherently intersect. However, a shared pathology connects I/R injury, HF, and inherited cardiomyopathies: the gradual loss of both physical coupling and functional coordination between mitochondrial translation, mem- brane insertion, and OXPHOS assembly. At the molecular level, this uncoupling initiates a severe proteotoxic cycle. Membrane depolarization directly stalls peptide elongation, while the simultaneous collapse of scaffolding complexes like MICOS and MITRAC leaves highly hydrophobic nascent subunits orphaned and prone to aggregation [34,81,110]. Concurrent redox stress, metabolic starvation, and epigenetic RNA modifications further suppress ribo- somal output. The temporal regulation of this decline remains highly context dependent. Acute insults like ischemia primarily disrupt early initiation events, whereas chronic failure often involves sustained epi- transcriptomic reprogramming through altered tRNA modifications and accelerated ribosome degradation. Ultimately, translational arrest evolves from a temporary protective pause into a primary source of widespread structural damage, driving cristae loss and triggering ter- minal quality control pathways. Identifying the exact molecular threshold where this adaptation becomes permanent dysfunction will dictate the success of future interventions. Because translational collapse actively drives pathology, rescuing this machinery offers a highly specific therapeutic angle. Instead of broadly stimulating cellular metabolism, newer approaches aim to resolve targeted translational bottlenecks. Compounds like SS-31 demonstrate the value of stabilizing the local lipid environment to ensure successful cotranslational membrane insertion [148,197]. Future drug design must move toward even greater precision, isolating specific initiation factors, epitranscriptomic enzymes, or structural assembly platforms. Concurrently, breakthrough genetic tools like base editors and organelle transplantation present opportunities to address root causes by permanently correcting or replacing defective genomic tem- plates [164,168]. To apply these tools effectively, the field urgently requires sensitive liquid biopsies capable of detecting circulating 13 Y. Deng et al. Redox Biology 92 (2026) 104143 ribosomal fragments or tRNA derivatives, allowing clinicians to stratify patients based on their specific translational defects. Future research must move beyond static measurements and actively track the dynamic real time progression of mitochondrial RNA pro- cessing, epitranscriptomics, and ribosome assembly. High resolution spatial and multi-omic profiling will be vital for mapping the exact in vivo trajectory of translational decline. Ultimately, cardiovascular medicine must pivot from simply managing late stage energy deficits toward proactively preserving the molecular machinery that builds the respiratory chain. By safeguarding the delicate interface between pro- tein synthesis and structural assembly, stabilizing mitochondrial trans- lation stands out as a foundational strategy for long term cardiac repair. CRediT authorship contribution statement Yunong Deng: Investigation, Visualization, Writing – original draft. Ningning Guo: Funding acquisition, Investigation, Visualization, Writing – original draft, Writing – review & editing. Die Li: Investiga- tion, Writing – original draft. Zhihua Wang: Conceptualization, Fund- ing acquisition, Project administration, Resources, Supervision, Writing – review & editing.

  generalfuture workevidence 5/5
  Keywords: assembly translational writing mitochondrial highly like molecular structural future specific must original draft translation beyond
• Echoes in the powerhouse: mito-lncRNAs contribution to cardiac function and disease (2026) · Acta Pharmacologica Sinica · doi

  Mito-lncRNAs have emerged as key regulators of cardiac influencing bioenergetics, oxidative mitochondrial homeostasis, stress responses, calcium handling, and mitochondrial quality control. Dysregulation of molecules such as LIPCAR, MALAT1, RMRP, H19, and lncND5 has been linked to AMI, heart failure, Acta Pharmacologica Sinica (2026) 0:1 – 17 cardiomyopathy, and pulmonary hypertension [37, 41, 55, 88, 90]. Several of these transcripts demonstrate promising diagnostic and prognostic performance in early clinical studies. Preclinical models further suggest that correcting disease-associated mitochondrial lncRNA imbalances can partially restore mitochondrial function these findings and attenuate cardiac dysfunction. Together, position mito-lncRNAs as mechanistically informative candidates therapeutic for biomarker development modulation. and, potentially, compartment-specific mechanisms, However, the field remains in an early translational stage, and key challenges must be addressed systematically. Methodological limita- tions in defining true mitochondrial localization, an incomplete limited of understanding sequence conservation across species, and inefficient delivery to the heart and mitochondria remain major barriers. To address these challenges, future work should explicitly link each challenge to targeted experimental strategies. Detection and localization issues will require orthogonal validation, including rigorously controlled mito- chondrial fractionation, high-resolution RNA imaging, and emerging single-cell and spatial transcriptomic approaches. These methods help distinguish genuine mitochondrial signals from nuclear or cytoplasmic ones. Mechanistic ambiguity should be addressed with compartment- restricted gene-editing or silencing tools, RNA–protein interactome mapping, and structure–function analyses to identify the domains and interactions that drive mitochondrial phenotypes. To improve translational relevance, greater emphasis should be placed on human iPSC-derived cardiomyocytes, engineered cardiac tissues, organoids, and humanized or large-animal models that better capture human- specific lncRNA regulation. On the therapeutic front, progress will depend on developing cardiotropic and mitochondria-directed RNA delivery platforms—such as optimized viral vectors, lipid-based systems, or RNA constructs incorporating targeting motifs—alongside standardized frameworks for assessing biodistribution, immunogeni- city, and long-term safety. For biomarker translation, large, multi- center, and ethnically diverse prospective studies with harmonized assay protocols will be essential to determine whether mito-lncRNA signatures provide robust, incremental value over existing clinical these methodological and translational challenges are tools. addressed in a coordinated manner, mito-lncRNAs have the potential to contribute meaningfully to more precise risk stratification and to targeted modulation of mitochondrial dysfunction in cardiovascular disease.

  generalfuture workevidence 5/5
  Keywords: mitochondrial mito lncrnas cardiac lncrna translational challenges addressed heart early clinical models disease function dysfunction
• Mitochondria in health and disease: cellular powerhouses, signaling centers, and drivers of dysfunction (2026) · Frontiers in Cell and Developmental Biology · doi

  Mitochondria have evolved far beyond their familial role as ATP generators. These organelles function as cellular centres that integrate energy metabolism, calcium homeostasis, redox signalling, and programmed cell death. Their dynamic nature, manifested via coordinated series of biogenesis, fusion, fission, and mitophagy, enables precise adaptation to physiological demands across diverse tissues. Consequently, mitochondrial integrity is essential to cellular and organismal health. Mitochondrial dysfunction, arising from bioenergetic failure, genetic mutations, or oxidative stress, is implicated in several pathologies, such as metabolic syndrome, neurodegenerative reproductive dysfunction, disorders, cardiovascular disease, cancer, and ageing. This review has systematically highlighted the molecular mechanisms of mitochondrial function and dysfunction, linking mitochondrial impairment to disease pathogenesis and exploring emerging therapeutic strategies. The therapeutic landscape has expanded considerably. Targeted antioxidants (MitoQ, SkQ1) neutralise pathological ROS at their source; PGC-1α activators and NAD+ precursors rejuvenate mitochondrial networks; gene-editing technologies (mitoTALENs, mtZFNs) offer potential to eliminate pathogenic mtDNA mutations; and mitochondrial transplantation represents a paradigm-shifting approach to organelle replacement. Yet clinical translation is limited. The failure of MitoQ in Phase II trials for Parkinson’s disease, hepatitis C, and ALS underscores the gap between preclinical promise and clinical reality, highlighting inadequate BBB penetration, lack of robust biomarkers, and failure to address upstream bioenergetic defects rather than downstream ROS. Future research must prioritize overcoming delivery barriers, especially the blood–brain barrier, through receptor-mediated transcytosis, extracellular vesicles, and focused ultrasound. Tissue-specific targeting using engineered lipid nanoparticles and is vital. Regulatory challenges, mitochondriotropic peptides including the lack of validated surrogate endpoints, disease heterogeneity, and evolving frameworks for gene-editing and mitochondrial replacement, need collaborative regulatory science and adaptive trial designs. Ethical considerations surrounding germline modification, identity, equity, and informed consent require engagement. Improved preclinical models, including patient-derived iPSCs and therapies addressing multiple organoids, and combination pathogenic mechanisms simultaneously, are critical for successful translation. The future of mitochondrial medicine does not lie in a single “magic bullet” but in the integration of sophisticated delivery science, rigorous regulation, thoughtful ethics, and interdisciplinary collaboration, symptomatic management to restoration of mitochondrial health. and public transitioning transparent governance eventually from

  generalfuture workevidence 5/5
  Keywords: mitochondrial disease dysfunction failure function cellular health bioenergetic mutations mechanisms therapeutic mitoq gene editing pathogenic

Questions about this gap